The RS isn't the most improtnant issue facing GTCB. The need to obtain $10 to $20 million and reduce the cash burn until rATIII is approved by the FDA are far more critical.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.